Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The mechanism of action of pertuzumab, a recombinant anti-HER2 humanized monoclonal antibody, is complementary to trastuzumab's. On 8 June 2012, the Food and Drug Administration approved the combination of pertuzumab with trastuzumab and docetaxel as first-line treatment of HER2-positive metastatic breast cancer. Furthermore, pertuzumab is the first drug to be approved in the neoadjuvant setting using a pathological complete response as an endpoint. Areas covered: The review provides insights into the main mechanisms of action of pertuzumab. In addition, it gives complete coverage of the landmark clinical and translational trials for this agent. Expert opinion: The new therapeutic algorithm in the treatment of HER2-positive advanced disease and the awaited results of the Aphinity trial are expected to impact the sequence of anti-HER2 treatment. Accordingly, the value of pertuzumab beyond progression needs to be properly studied. Furthermore, to improve the toxicity profile and efficacy of future treatment, new pertuzumab-based regimens are being investigated.

          Related collections

          Author and article information

          Journal
          Expert Opin Biol Ther
          Expert opinion on biological therapy
          Informa UK Limited
          1744-7682
          1471-2598
          Mar 2017
          : 17
          : 3
          Affiliations
          [1 ] a Department of Medical and Biological Sciences , University of Udine , Udine , Italy.
          [2 ] b Department Oncology , University Hospital of Udine , Udine , Italy.
          Article
          10.1080/14712598.2017.1282944
          28092723

          Comments

          Comment on this article